

# Predicting Clinical Trial Success

**Team:** Richard Do, Nathan Maton

**In partnership with:** Yamina Hakem,  
Brian Lucena, and Jason Moore from




**GlobalReach BI**

Turning data into profits



**How would you make a \$2.6 billion  
decision?**

# Industry Standard Uses Basic Probability of Success



Source: Biomedtracker 2006-2015 report

# Problem Statement: Predict Success and Time to Market

---

Can we predict:

1. Whether a drug will succeed?
2. Which drug will be first to market and quantify the time?



# Strategy - Focus on Breast Cancer

---

## Clean trials data

Extract drug features from ADIS Insight trial database



## Model success

Use markov chains with each trial phase getting its own state




## Test in industry

Work with industry partners and assess value

# Simple Markov Chain Explanation

---



# Engineer Features

---

- Subjects in each phase
- Organizations for drug
- Trial centers
- Trial length
- Trial design (12 types, e.g. Randomized)

# Question 1: Predict Drug Success




# Drivers of Success

---

	# of Subjects	# of Orgs	Prospective Trial Design
Phase I	Neg	Pos	-
Phase II	Neg	Pos	Pos
Phase III	Pos	Neg	Pos

# Model Improvement Over Industry Standard by 14%



Impact:


360+ million

on average, cost savings for  
drug development


*Assumption: Phase success is independent*

# Question 2: Predict First to Market

# Expected Trial Lengths Vary Per Phase



# Predicted Phase Completion Better than Industry Standard



Impact:

**+12% market share**

for first drug to market, on average (300+ million/year)

([source](#))

*Assumption: Phase length is independent*

# Exciting Results for Partnership Meetings Next Week

---

- Can make \$360+ million, on average, more per drug developed
- First drug to market gains 12% more revenue on average
- Engineering features are the drive to model improvement
- Scale to other diseases



# Contact information

---



Richard Do



/rdooooooo/



in/rdo/



richardddo@gmail.com



Nathan Maton



/NathanMaton/



in/nathanmaton/



nathanmaton@gmail.com

# Thanks!

...



# Appendix


...

# Tools used

---











Natural Language Analysis



docker



# Key features to understand drivers of trial length

	# of subjects	# of Orgs	Prospective trial design
Phase I			
Phase II			
Phase III		-	

# Methodology - Two data sources

---

## Data Available

- **Clinical Trials:** Data about clinical trials to help Breast Cancer starting in 2000
- **Drug data:** Data about drug characteristics in same timeframe

